# Halozyme Shares Fall More Than 13% After Leerink Downgrade By Enna Lee Canonical URL: https://www.tokenpost.com/news/investing/51610 Published: 2026-11-08T13:13:53.000Z Updated: 2026-11-08T13:13:53.000Z Section: Investing > Third-quarter revenue rose 39% to $493 million, while non-GAAP earnings came in 3 cents above estimates. Halozyme Therapeutics (HALO) shares fell more than 13% Friday, Nov. 6, after Leerink Partners downgraded the drug-delivery technology developer following a quarter that only marginally exceeded analyst forecasts. The company reported third-quarter revenue of $493 million, up 39% from a year earlier. Non-GAAP earnings were $2.39 per share, 3 cents above estimates, while revenue exceeded estimates by $1.44 million. Halozyme also [raised its 2026 revenue outlook to $1.86 billion to $1.925 billion](). ## Links in this article - [raised its 2026 revenue outlook to $1.86 billion to $1.925 billion](https://www.tokenpost.com/news/business/50766)